Phosphorylated Antigen-Alum Complexes for Stable Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines face limitations due to insufficient antigen retention and immune response, often resulting in poor targeting to lymph nodes and adverse reactions from conventional adjuvants, which can decrease vaccine effectiveness and increase safety concerns.
Innovation Solution
The development of antigen-adjuvant complexes where antigens are covalently linked to a multivalent adjuvant-reactive moiety, specifically using phosphorylated amino acid residues like phosphoserine to form tight bonds with metal hydroxide adjuvants like alum, enhancing immune response and antigen presentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional adjuvants are used to enhance immune response, then immune response is improved, but adverse reactions such as toxicity and local inflammation increase
Solution Approach 1:
The invention changes the chemical parameters of the adjuvant-antigen interaction by using site-specific phosphorylated amino acid residues (phosphoserine, phosphothreonine, phosphotyrosine) that have high affinity for aluminum hydroxide adjuvants. This specific chemical modification (phosphorylation) alters how the antigen binds to the adjuvant, creating stable complexes that enhance immune response while reducing adverse reactions through controlled interaction.
Solution Approach 2:
The invention applies local quality by introducing phosphorylated amino acid residues at specific locations on the antigen molecule rather than modifying the entire antigen uniformly. This site-specific modification allows selective binding to aluminum hydroxide adjuvants at particular epitopes, enhancing local immune recognition while maintaining overall antigen structure and reducing non-specific adverse reactions.
2Reliability
If antigen retention is increased to improve immune response, then immune response is improved, but antigen clearance time increases
Solution Approach 1:
The invention changes the binding affinity parameter between antigen and adjuvant by introducing phosphorylated amino acid residues that form stable complexes with aluminum hydroxide. This parameter change increases antigen retention at the injection site and in lymph nodes, allowing prolonged immune response without excessive accumulation that would cause toxicity.
Solution Approach 2:
The invention creates a dynamic balance in antigen retention by using reversible but stable phospho-aluminum complexes. The antigen-adjuvant complexes are retained long enough to elicit strong immune responses in lymph nodes, but can still be cleared naturally over time, providing controlled duration of action rather than permanent retention.
3Reliability
If site-specific conjugation is used to improve antigen orientation, then immune response is improved, but manufacturing complexity increases
Solution Approach 1:
The invention applies preliminary action by introducing phosphorylated amino acid residues into the antigen sequence during recombinant protein expression before the antigen is purified and formulated. This site-specific modification is built into the antigen production process itself, rather than requiring complex post-purification conjugation steps, thus improving antigen orientation while minimizing manufacturing complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases antibody titers and germinal center responses, providing enhanced humoral immunity and prolonged antigen retention at injection sites, while reducing adverse reactions by ensuring targeted and stable antigen delivery to lymph nodes.
Implementation Method 1
site-specific introduction of multivalent PS peptide-polymer affinity linkers, which undergo ligand exchange reactions with the surface of alum to anchor antigens
Implementation Method 2
an antigen covalently linked to an antigen-reactive moiety that is coupled, optionally via at least one linker, to a multivalent adjuvant-reactive moiety comprising two or more hydroxyl-replacement groups
Data Source
AI summary
The present disclosure relates to compositions and methods for coupling an antigen to an adjuvant, immunogenic compositions and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.